Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles Encapsulating Fenbendazole and Rapamycin in Ovarian Cancer
International Journal of Nanomedicine · 2023-05 · Volume 18 · 2209-2223
DOI: 10.2147/ijn.s394712 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2023-05. Verfasst von Yu Been Shin und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Chungbuk National University, Cheongju, 28160, Republic of Korea. Hauptthemen laut MEDLINE: Micelles, Ovarian Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
We aimed to inhibit ovarian cancer (OC) development by interfering with microtubule polymerization and inhibiting mTOR signaling. To achieve this, previously developed micelles containing fenbendazole and rapamycin were applied.
Methods
Herein, we prepared micelles for drug delivery using fenbendazole and rapamycin at a 1:2 molar ratio and methoxy poly(ethylene glycol)-b-poly(caprolactone)(mPEG-b-PCL) via freeze-drying. We revealed their long-term storage capacity of up to 120 days. Furthermore, a cytotoxicity test was performed on the OC cell line HeyA8, and an orthotopic model was established for evaluating in vivo antitumor efficacy.
Results
Fenbendazole/rapamycin-loaded mPEG-b-PCL micelle (M-FR) had an average particle size of 37.2 ± 1.10 nm, a zeta potential of -0.07 ± 0.09 mV, and a polydispersity index of 0.20 ± 0.02. Additionally, the average encapsulation efficiency of fenbendazole was 75.7 ± 4.61% and that of rapamycin was 98.0 ± 1.97%. In the clonogenic assay, M-FR was 6.9 times more effective than that free fenbendazole/rapamycin. The in vitro drug release profile showed slower release in the combination formulation than in the single formulation.
Conclusion
There was no toxicity, and tumor growth was suppressed substantially by our formulation compared with that seen with the control. The findings of our study lay a foundation for using fenbendazole and rapamycin for OC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Chungbuk National University, Cheongju, 28160, Republic of Korea.
- Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
- Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
ORCID-Profile: Ju-Yeon Choi, Jeong-Won Lee
Zitieren
APA
Shin, Y. B., Choi, J. Y., Shin, D. H., & Lee, J. W. (2023). Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles Encapsulating Fenbendazole and Rapamycin in Ovarian Cancer. International Journal of Nanomedicine, Volume 18, 2209-2223. https://doi.org/10.2147/ijn.s394712
Vancouver
Shin YB, Choi JY, Shin DH, Lee JW. Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles Encapsulating Fenbendazole and Rapamycin in Ovarian Cancer. International Journal of Nanomedicine. 2023;Volume 18:2209-2223. doi:10.2147/ijn.s394712
BibTeX
@article{Shin2023,
author = {Shin, Yu Been and Choi, Ju-Yeon and Shin, Dae Hwan and Lee, Jeong-Won},
title = {Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles Encapsulating Fenbendazole and Rapamycin in Ovarian Cancer},
journal = {International Journal of Nanomedicine},
year = {2023},
volume = {Volume 18},
pages = {2209--2223},
doi = {10.2147/ijn.s394712}
}
EUVIMED